🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT04884802
Recruiting Not applicable

The GUARDIAN Trial

NCT04884802 · tracked via the Priya Life Science China tracker
Sponsor
The University of Texas Health Science Center, Houston
Phase
Not applicable
Started
2021-07-25
Last updated
2025-08-29

Condition(s) studied

Blood Pressure

Investigational drug(s) / intervention(s)

Tight blood pressure managementRoutine blood pressure management

Tight blood pressure management: Norepinephrine or phenylephrine infusion to maintain intraoperative MAP ≥85 mmHg.

Routine blood pressure management: ACEIs, ARBs, and/or calcium channel blockers can be given the morning of surgery if deemed appropriate by the attending anesthesiologist. Intraoperative blood pressure will be managed per clinical routine.

Study summary

An international randomized trial to test the primary hypothesis that perioperative tight blood pressure management reduces a composite of major perfusion-related complications (myocardial injury, stroke, non-fatal cardiac arrest, Stage 2-3 acute kidney injury, deep or organ-space infection, sepsis, and death) in the 30 days after major non-cardiac surgery.

The treatments will be: 1) norepinephrine or phenylephrine infusion to maintain intraoperative MAP ≥85 mmHg (tight pressure management); or, 2) routine intraoperative blood pressure management (routine pressure management).

Eligibility

Sex
ALL
Min age
45 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. At least 45 years old; 2. Scheduled for major noncardiac surgery expected to last at least 2 hours; 3. Having general anesthesia, neuraxial anesthesia, or the combination; 4. Expected to require at least overnight hospitalization (planned ICU admission is acceptable); 5. Are designated ASA physical status 2-4 (ranging from mild systemic disease through severe systemic disease that is a constant threat to life); 6. Expected to have direct intraoperative blood pressure monitoring with an arterial catheter; 7. Cared for by clinicians willing to follow the GUARDIAN protocol; 8. Subject to at least one of the following risk factors: 1. Age \>65 years; 2. History of peripheral arterial disease; 3. History of coronary artery disease; 4. History of stroke or transient ischemic attack; 5. Serum creatinine \>175 μmol/L (\>2.0 mg/dl) within 6 months; 6. Diabetes requiring medication; 7. Current smoking or 15 pack-year history of smoking tobacco; 8. Scheduled for major vascular surgery; 9. Body mass index ≥35 kg/m2; 10. Preoperative high-sensitivity troponin T \>14 ng/L or troponin I equivalent, defined as ≥15 ng/L (Abbott assay), 19 ng/L (Siemens assay, \[Borges, unpublished\]), or 25% of the 99% percentile for other assays - all within 6 months; 11. B-type natriuretic protein (BNP) \>80 ng/L or N-terminal B-type natriuretic protein (NTProBNP) \>200 ng/L within six months. Exclusion Criteria: 1. Are scheduled for carotid artery surgery; 2. Are scheduled for intracranial surgery; 3. Are scheduled for partial or complete nephrectomy; 4. Are scheduled for pheochromocytoma surgery; 5. Are scheduled for liver or kidney transplantation; 6. Require preoperative intravenous vasoactive medications; 7. Have a condition that precludes routine or tight blood pressure management such as surgeon request for relative hypotension; 8. Require beach-chair positioning; 9. Have a documented history of dementia; 10. Have language, vision, or hearing impairments that may compromise cognitive assessments; 11. Have contraindications to norepinephrine or phenylephrine per clinician judgement; 12. Have previously participated in the GUARDIAN trial.

Primary outcome measure(s)

Trial sites (20)

FacilityCityRegionStatus
University of Nebraska Medical Center Omaha Nebraska Completed
Wake Forest University Wake Forest North Carolina Completed
MetroHealth Medical Center Cleveland Ohio Recruiting
Cleveland Clinic Fairview Hospital Cleveland Ohio Completed
Cleveland Clinic Main Campus Cleveland Ohio Completed
The University of Texas Health Science Center at Houston Houston Texas Recruiting
Beijing Shijitan Hospital, Capital Medical University Beijing China Recruiting
Peking Union Medical College Hospital Beijing China Recruiting
Peking University First Hospital Beijing China Recruiting
West China University Hospital Chengdu China Recruiting
Prince of Wales Hospital, Chinese University of Hong Kong, Shatin Hong Kong China Recruiting
Renji Hospital, Shanghai Jiaotong University School of Medicine Shanghai China Recruiting
Shanghai Chest Hospital Shanghai China Recruiting
Shanghai Ninth People's Hospital Shanghai China Recruiting
The Affiliated Lianyungang Hospital of Xuzhou Medical University Xuzhou China Recruiting
University of Thessaly Larissa Greece Completed
IRCCS Regina Elena National Cancer Institute Rome Italy Recruiting
National Defense Medical College Tokyo Japan Recruiting
Bakirkoy Dr. Sadi Konuk Research and Training Hospital Bakırköy Turkey (Türkiye) Recruiting
Konya City Hospital Konya Turkey (Türkiye) Recruiting

More The University of Texas Health Science Center, Houston trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04884802 on ClinicalTrials.gov ↗ ← All trials in China